Published in Clin Infect Dis on July 01, 1998
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am (2009) 1.19
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother (2009) 1.12
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.08
Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites. J Periodontol (2000) 1.07
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother (2001) 0.95
Determination of ciprofloxacin in human plasma using high-performance liquid chromatography coupled with fluorescence detection: application to a population pharmacokinetics study in children with severe malnutrition. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.88
Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother (2001) 0.88
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother (2000) 0.84
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob Agents Chemother (2002) 0.83
Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob Agents Chemother (2000) 0.81
Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomedicine (2011) 0.80
Safety Concerns Surrounding Quinolone Use in Children. J Clin Pharmacol (2016) 0.78
Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration. J Vet Sci (2008) 0.78
Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Antimicrob Agents Chemother (2002) 0.76
Dispositions of enrofloxacin and its major metabolite ciprofloxacin in Thai swamp buffaloes. J Vet Med Sci (2015) 0.75
Vertigo/dizziness as a Drugs' adverse reaction. J Pharmacol Pharmacother (2013) 0.75
Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats. ISRN Vet Sci (2011) 0.75
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrob Agents Chemother (2015) 0.75
Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. Vet Med Int (2014) 0.75
Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administration. Vet Med Int (2010) 0.75
Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. Front Vet Sci (2017) 0.75
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54
Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23
A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed (1980) 2.03
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
67 Ga for tumor scanning. J Nucl Med (1972) 1.97
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
[Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase]. Z Klin Chem Klin Biochem (1970) 1.53
Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46
Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother (1982) 1.42
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (2001) 1.37
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Comparative pharmacokinetics of new quinolones. Drugs (1987) 1.22
Reliability of drug history in analgesic users. Lancet (1984) 1.21
Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol (1989) 1.12
[Congenital nonspherocytic hemolytic anemia, cataract and glucose-6-phosphate dehydrogenase deficiency]. Dtsch Med Wochenschr (1966) 1.11
Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol (1983) 1.08
Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000) 1.01
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2001) 0.99
Measurement of lung density by computed tomography. J Comput Assist Tomogr (1978) 0.99
Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Antimicrob Agents Chemother (1998) 0.99
Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother (1980) 0.98
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother (1988) 0.97
Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem (1986) 0.97
[Blood levels of cephalothin in normal and impaired renal function]. Int Z Klin Pharmakol Ther Toxikol (1972) 0.96
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis (1976) 0.94
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother (1994) 0.92
Concentrations of ofloxacin in human bone and in cartilage. J Antimicrob Chemother (1990) 0.92
Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother (1998) 0.91
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother (1987) 0.90
Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc (2001) 0.90
Pharmacokinetics of Cefmenoxime in normal and impaired renal function. Arzneimittelforschung (1983) 0.90
[Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA-II) (author's transl)]. J Clin Chem Clin Biochem (1977) 0.89
[Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)]. Arzneimittelforschung (1981) 0.89
Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother (1997) 0.88
[Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)]. Arzneimittelforschung (1980) 0.88
Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother (1996) 0.88
Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function. Clin Pharmacol Ther (1984) 0.88
Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. Antimicrob Agents Chemother (1987) 0.88
Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs (1988) 0.87
Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother (1990) 0.87
Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit (1987) 0.87
Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J (1997) 0.86
Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother (1990) 0.86
Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis (1993) 0.86
Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother (1990) 0.85
[The use of a digital computer in the development of dosage recommendations for antibiotic therapy]. Arzneimittelforschung (1972) 0.85
Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection (1990) 0.85
Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother (1993) 0.85
Pharmacokinetics and dose recommendations of carumonam in renal failure. Arzneimittelforschung (1987) 0.84
Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother (1993) 0.84
Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy (1985) 0.83
Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. J Antimicrob Chemother (1988) 0.83
Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. J Infect Dis (1976) 0.83
Penetration of amoxycillin/clavulanate into human bone. J Antimicrob Chemother (1989) 0.83
[Pharmacokinetics of carbenicillin in high dosage (author's transl)]. Dtsch Med Wochenschr (1974) 0.83
[Dosage of Cefoperazone in Normal and Restricted Renal Function (author's transl]. MMW Munch Med Wochenschr (1982) 0.82
Pharmacokinetics of ciprofloxacin in liver cirrhosis. Chemotherapy (1990) 0.82